Given the high heterogeneity of SLE, the clinical utility of EEF1A1 as a serum biomarker requires further validation in prospective cohorts, particularly its correlation with SLEDAI scores and lupus nephritis flares [48]. The gene discussed is EEF1A1; the disease is lupus nephritis.